Connor, Clark & Lunn Investment Management (CC&L)’s Emergent Biosolutions EBS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.38M	Sell	648,377 -129,622	-17%	-$1.34M	0.01%	666
2025 Q4	$9.62M	Sell	777,999 -354,306	-31%	-$3.8M	0.03%	471
2025 Q3	$9.99M	Buy	1,132,305 +145,632	+15%	+$1.13M	0.03%	412
2025 Q2	$6.29M	Buy	986,673 +55,046	+6%	+$315K	0.02%	516
2025 Q1	$4.53M	Buy	931,627 +29,295	+3%	+$242K	0.02%	525
2024 Q4	$8.63M	Buy	902,332 +69,157	+8%	+$635K	0.04%	360
2024 Q3	$6.96M	Sell	833,175 -10,213	-1%	-$92.8K	0.03%	364
2024 Q2	$5.75M	Buy	843,388 +137,153	+19%	+$590K	0.02%	397
2024 Q1	$1.79M	Buy	706,235 +495,781	+236%	+$1.12M	0.01%	704
2023 Q4	$505K	Buy	210,454 +920	+0.4%	+$2.16K	﹤0.01%	1045
2023 Q3	$712K	Buy	+209,534	New	+$1.16M	﹤0.01%	929
2023 Q2	–	Sell	-45,855	Closed	-$475K	–	1366
2023 Q1	$475K	Buy	+45,855	New	+$554K	﹤0.01%	898
2020 Q4	–	Sell	-39,350	Closed	-$4.07M	–	934
2020 Q3	$4.07M	Buy	39,350 +16,929	+76%	+$1.82M	0.03%	344
2020 Q2	$1.77M	Buy	+22,421	New	+$1.67M	0.01%	481
2016 Q1	–	Sell	-50,400	Closed	-$2.02M	–	849
2015 Q4	$2.02M	Buy	50,400 +9,900	+24%	+$345K	0.02%	338
2015 Q3	$1.15M	Buy	40,500 +34,400	+564%	+$1.13M	0.01%	377
2015 Q2	$201K	Buy	+6,100	New	+$189K	﹤0.01%	562
2014 Q2	–	Sell	-54,011	Closed	-$1.51M	–	556
2014 Q1	$1.51M	Buy	54,011 +23,900	+79%	+$604K	0.01%	314
2013 Q4	$736K	Sell	30,111 -700	-2%	-$14.6K	0.01%	427
2013 Q3	$603K	Buy	30,811 +5,711	+23%	+$102K	0.01%	329
2013 Q2	$382K	Buy	+25,100	New	+$363K	﹤0.01%	392

Other funds holding EBS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Connor, Clark & Lunn Investment Management (CC&L)'s EBS Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Emergent Biosolutions (EBS) stake by 17% in Q1 2026, selling an estimated $1.34M and leaving 648,377 shares worth $5.38M. The position accounts for 0.01% of the portfolio, ranked #666.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EBS in Q2 2013 and has held it in 21 quarters since. The position peaked at $9.99M in Q3 2025. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 648,377 shares of Emergent Biosolutions worth $5.38M as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 129,622 Emergent Biosolutions shares in Q1 2026, an estimated $1.34M.
Emergent Biosolutions made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #666 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 21 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Emergent Biosolutions position peaked at $9.99M in Q3 2025.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.